Pfizer's Celebrex, Bextra Targets Of Public Citizen Withdrawal Petition
This article was originally published in The Pink Sheet Daily
Executive Summary
Public Citizen tells FDA that COX-2 inhibitors have inherent cardiovascular risks and offer no efficacy advantages over non-selective NSAIDs. The group suggests the mechanism that creates the COX-2 inhibitors' thrombogenicity is "increased platelet-vessel wall interactions and firm adhesions."